scholarly journals Serum phosphate as an additional marker for initiating hemodialysis in patients with advanced chronic kidney disease

2015 ◽  
Vol 38 (6) ◽  
pp. 531-537 ◽  
Author(s):  
Yueh-An Lu ◽  
Shen-Yang Lee ◽  
Hui-Yi Lin ◽  
Yen-Chun Liu ◽  
Huang-Kai Kao ◽  
...  
Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3605
Author(s):  
Ping-Huang Tsai ◽  
Hsiu-Chien Yang ◽  
Chin Lin ◽  
Chih-Chien Sung ◽  
Pauling Chu ◽  
...  

Muscle wasting and hyperphosphatemia are becoming increasingly prevalent in patients who exhibit a progressive decline in kidney function. However, the association between serum phosphate (Pi) level and sarcopenia in advanced chronic kidney disease (CKD) patients remains unclear. We compared the serum Pi levels between advanced CKD patients with (n = 51) and those without sarcopenia indicators (n = 83). Low appendicular skeletal muscle mass index (ASMI), low handgrip strength, and low gait speed were defined per the standards of the Asian Working Group for Sarcopenia. Mean serum Pi level was significantly higher in advanced CKD patients with sarcopenia indicators than those without sarcopenia indicators (3.88 ± 0.86 vs. 3.54 ± 0.73 mg/dL; p = 0.016). Univariate analysis indicated that serum Pi was negatively correlated with ASMI, handgrip strength, and gait speed. Multivariable analysis revealed that serum Pi was significantly associated with handgrip strength (standardized β = −0.168; p = 0.022) and this association persisted even after adjustments for potential confounders. The optimal serum Pi cutoff for predicting low handgrip strength was 3.65 mg/dL, with a sensitivity of 82.1% and specificity of 56.6%. In summary, low handgrip strength is common in advanced CKD patients and serum Pi level is negatively associated with handgrip strength.


2019 ◽  
pp. 2-3

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].


Andrologia ◽  
2021 ◽  
Author(s):  
Haitham Elbardisi ◽  
Ahmad Majzoub ◽  
Christiana Daniel ◽  
Fadwa Al.Ali ◽  
Mohamed Elesnawi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document